Supplementary Figure 17 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
<p>Supplementary Figure 17. (A) Objective response rate, (B) progression-free survival, and (C) overall survival to PD-(L)1 inhibition among patients with advanced/metastatic NSCLC, according to ATM expression by immunohistochemistry.</p>
Sparad:
| Huvudupphovsman: | |
|---|---|
| Övriga upphovsmän: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Publicerad: |
2025
|
| Ämnen: | |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|
| Sammanfattning: | <p>Supplementary Figure 17. (A) Objective response rate, (B) progression-free survival, and (C) overall survival to PD-(L)1 inhibition among patients with advanced/metastatic NSCLC, according to ATM expression by immunohistochemistry.</p> |
|---|